Alemtuzumab vs. interferon beta-1a in early multiple sclerosis
The CAMMS223 Trial Investigators (2008) Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 359:1786–1801. doi:10.1056/NEJMoa0802670
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomized controlled phase 3 trial
COI: 1:CAS:528:DC%2BC38Xhs1ajtbjE, PID: 23122652
Cohen JA, Coles AJ, Arnold DL et al (2012) Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomized controlled phase 3 trial. Lancet 380:1819–1828
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomized phase 3 trial
COI: 1:CAS:528:DC%2BC38Xhs1ajtbjF, PID: 23122650
Coles AJ, Twyman CL, Arnold DL et al (2012) Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomized phase 3 trial. Lancet 380:1829–1839
Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis
COI: 1:CAS:528:DyaK1MXmtF2qtr4%3D, PID: 10482259
Coles AJ, Wing M, Molyneux P et al (1999) Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 46:296–304
Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis
COI: 1:STN:280:DyaK2czivVOmuw%3D%3D, PID: 7914262
Moreau T, Thorpe J, Miller D et al (1994) Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis. Lancet 344:298–301
The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy
PID: 16044212
Coles AJ, Cox A, Le Page E et al (2006) The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol 253:98–108
Esposito F, Radaelli M, Martinelli V et al (2010) Comparative study of mitoxantrone efficacy profile in patients with relapsing-remitting and secondary progressive multiple sclerosis. Mult Scler 16:1490–1499
Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicenter study of active disease using MRI and clinical criteria
COI: 1:STN:280:DyaK2s3gtVyrsg%3D%3D, PID: 9048709
Edan G, Miller D, Clanet M et al (1997) Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicenter study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 62:112–118
Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients
PID: 17846110
Le Page E, Leray E, Taurin G et al (2008) Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients. J Neurol Neurosurg Psychiatry 79:52–56
Edan G, Comi C, Le Page E et al (2011) Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial. J Neurol Neurosurg Psychiatry 82:1344–1350